On April 30, 2026 Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, reported that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society for Medical Oncology Gynaecological Cancers (ESMO GC) Annual Congress in Copenhagen, Denmark, June 17–19, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation

Title:
Bulumtatug Fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study.
Abstract No.: 28RO
Presenter: Prof. Yang Huijuan, Fudan University Shanghai Cancer Center
Session Date and Time: 6/17/2026 2:45PM-4:10PM (local time)

Poster Presentation

Title:
Preliminary results of Bulumtatug Fuvedotin (BFv, 9MW2821) in combined with Toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a Phase Ib/II Clinical Study.

Abstract No.: 36P
Principal Investigator:
Prof. Lou Hanmei, Zhejiang Cancer Hospital
Prof. Wang Yudong, International Peace Maternity and Child Health Hospital of China Welfare Institute
Session Date and Time: 6/18/2026 12:45PM-1:30PM (local time)

(Press release, Mabwell Biotech, APR 30, 2026, View Source;mabwell-to-present-latest-clinical-data-on-9mw2821-for-cervical-cancer-in-oral-and-poster-presentations-302758286.html [SID1234664984])